Surrozen, Inc.
SRZNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 25, 2026 | H.C. Wainwright | Matthew Caufield | $54.00(+60%) | $33.68 | StreetInsider |
| May 7, 2026 | H.C. Wainwright | $44.00(+29%) | $34.13 | TheFly | |
| Feb 19, 2026 | Cantor Fitzgerald | $40.00(+59%) | $25.09 | TheFly | |
| Jan 30, 2025 | H.C. Wainwright | Matthew Caufield | $32.00(+184%) | $11.25 | TheFly |
| Jan 3, 2025 | Guggenheim | Yatin Suneja | $45.00(+158%) | $17.45 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Mar 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2025 |
| Guggenheim | upgrade | Neutral →Buy | Jan 3, 2025 |
| JP Morgan | downgrade | Neutral →Underweight | Nov 28, 2022 |
| Guggenheim | downgrade | Buy →Neutral | Nov 17, 2022 |
| B of A Securities | downgrade | Neutral →Underperform | Nov 16, 2022 |
| JP Morgan | maintain | Neutral | Oct 17, 2022 |
| B of A Securities | downgrade | Buy →Neutral | May 26, 2022 |
| B of A Securities | maintain | Buy | Oct 11, 2021 |
| Guggenheim | maintain | Buy | Sep 15, 2021 |
| Stifel | maintain | Buy | Sep 7, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.41 | $-1.29 | $5.0M | $467.3K |
| May 6, 2026 | $-11.65 | $-1.39 | $5.0M | $4.0M |
| Mar 23, 2026 | $-19.13 | $-1.29 | $514.0K | $661.0K |
| Nov 7, 2025 | $-8.36 | $-1.17 | $983.0K | $983.0K |
| Aug 8, 2025 | $-1.14 | $-1.23 | $983.0K | — |
| May 9, 2025 | $-7.43 | $-1.09 | $991.5K | — |
| Mar 31, 2025 | $-9.10 | $-2.54 | $655.0K | — |
| Nov 6, 2024 | $-0.44 | $-2.77 | $10.0M | — |
News
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the closing of the second and final tranche of its March 2025 private placement of securities.
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Risk and Volatility Prelude Therapeutics has a beta
Surrozen (NASDAQ: SRZN - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Volatility and Risk Surrozen has a beta of
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic …
Surrozen Inc. (NASDAQ:SRZN) skyrocketed on Thursday after the company submitted an Investigational New Drug application to the U.S. Food and Drug Administration to evaluate SZN-8141 for treating diabetic macular edema.
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endo…
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences.